Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02049593 | PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors | PHASE1 | COMPLETED | 44 | — | — | Jun 12, 2014 | Oct 7, 2019 | Sep 26, 2022 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Arm A (PARP inhibitor BMN-673, temozolomide) | EXPERIMENTAL | Patients receive PARP inhibitor BMN-673 PO QD on days 1-28 and temozolomide PO daily on days1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
| Arm B (PARP inhibitor BMN-673, irinotecan hydrochloride) | EXPERIMENTAL | Patients receive PARP inhibitor BNM-673 as in Arm A and irinotecan hydrochloride IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
| Name | Type | Description |
|---|---|---|
| PARP inhibitor BMN-673 | DRUG | Given PO |
| temozolomide | DRUG | Given PO |
| irinotecan hydrochloride | DRUG | Given IV |
| pharmacological study | OTHER | Correlative studies |
| laboratory biomarker analysis | OTHER | Correlative studies |
Inclusion Criteria: * Histologically or cytologically documented, unresectable, locally advanced or metastatic solid tumor for which no standard therapy is recognized or for which standard therapy has failed * Measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |